Serum levels of soluble interleukin‐2 receptor

Yosef Uziel, Bernice R. Krafchik, Brian Feldman, Earl D. Silverman, Laurence A. Rubin, Ronald M. Laxer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Objective. To determine whether circulating serum levels of soluble interleukin‐2 receptor (sIL‐2R) are elevated in patients with localized scleroderma, and if levels of sIL‐2R can differentiate between active and inactive disease. Methods. Seventeen patients with localized scleroderma were categorized by overall physician assessment into active, inactive, and indeterminate groups, according to disease activity. Serum sIL‐2R levels were analyzed and correlated with disease activity. Results. The mean sIL‐2R level was significantly higher (P = 0.005) in those with active disease (1,675 ± 823 units/ml) than in those with inactive disease (722 ± 218 units/ml). Conclusion. Serum sIL‐2R levels are elevated in patients with localized scleroderma. When present, elevated sIL‐2R levels appear to be able to differentiate active from inactive disease. This fact also suggests cell‐mediated immune activation in this condition. Further serial studies are required to assess the value and sensitivity of sIL‐2R levels in measuring changes in disease activity.

Original languageEnglish
Pages (from-to)898-901
Number of pages4
JournalArthritis and Rheumatology
Issue number6
StatePublished - Jun 1994
Externally publishedYes


Dive into the research topics of 'Serum levels of soluble interleukin‐2 receptor'. Together they form a unique fingerprint.

Cite this